Leo I. Gordon, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses novel immunomodulatory agents and standard treatment options for patients with relapsed or refractory Hodgkin lymphoma.
Christina S. Chu, MD, of Fox Chase Cancer Cen...
Margaret A. Tempero, MD, of the UCSF Helen Di...
Suzanne George, MD, of Dana-Farber Cancer Ins...
Paul M. Cinciripini, PhD, of The University o...
David G. Pfister, MD, of Memorial Sloan Kette...